Androgens and breast cancer risk

Gynecological Endocrinology

Volumn 28, Issue SUPPL.1, 2012, Pages 46-49

  Kenemans, Peter ^a   Van Der Mooren, Marius J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgens; breast cancer; breast cancer risk; female sexual dysfunction; libido; testosterone; transdermal patch

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN; GESTAGEN; TESTOSTERONE; TIBOLONE;

ACNE; APPLICATION SITE REACTION; AROMATIZATION; BODY FAT; BONE DENSITY; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CARDIOVASCULAR DISEASE; CLITEROMEGALY; COGNITION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG IMPLANT; DRUG SAFETY; FEMALE; GENITAL SYSTEM DISEASE; HAIR DISEASE; HIRSUTISM; HORMONAL THERAPY; HUMAN; KIDNEY FUNCTION; LIBIDO DISORDER; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; LOW DRUG DOSE; METHODOLOGY; MOOD; MOTOR PERFORMANCE; MUSCLE MASS; PATIENT COUNSELING; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; TEMPORAL BALDING; VOICE DEEPENING; WELLBEING;

ANDROGENS; ANIMALS; BREAST NEOPLASMS; CARCINOMA; COUNSELING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; RISK FACTORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84858042285     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.651925     Document Type: Review

References (51)

1. Genazzani AR, Pluchino N, Freschi L, Ninni F, Luisi M. Androgens and the brain. Maturitas 2007;57:27-30. (Pubitemid 46602886)
2. Genazzani AR, Pluchino N. Androgen replacement therapy and cardiovascular function. Climacteric 2009;12 Suppl 1:102-107.
3. Nappi RE, Albani F, Valentino V, Polatti F, Chiovato L, Genazzani AR. Aging and sexuality in women. Minerva Ginecol 2007;59:287-298. (Pubitemid 47208112)
4. Cameron DR, Braunstein GD. Androgen replacement therapy in women. Fertil Steril 2004;82:273-289. (Pubitemid 39092019)
5. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-2838. (Pubitemid 32269161)
6. Nappi RE, Nijland EA. Women's perception of sexuality around the menopause: outcomes of a European telephone survey. Eur J Obstet Gynecol Reprod Biol 2008;137:10-16. (Pubitemid 351635671)
7. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006;13:46-56.
8. Graziottin A. Prevalence and evaluation of sexual health problems - HSDD in Europe. J Sex Med 2007;4 Suppl 3:211-219. (Pubitemid 46372029)
9. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006;3:212-222.
10. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001;56:361-376. (Pubitemid 32520648)
11. Bui HN, Struys EA, Martens F, de Ronde W, Thienpont LM, Kenemans P, Verhoeven MO, et al. Serum testosterone levels measured by isotope dilution-liquid chromatography-tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy. Ann Clin Biochem 2010;47:248-252.
12. Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P, Lachowsky M, et al. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric 2010;13:103-120.
13. Genazzani AR, Pluchino N, Bernardi F, Centofanti M, Luisi M. Beneficial effect of tibolone on mood, cognition, well-being, and sexuality in menopausal women. Neuropsychiatr Dis Treat 2006;2:299-307. (Pubitemid 44574146)
14. Kenemans P. Tibolone revisited: still a good treatment option for healthy, early postmenopausal women. Gynecol Endocrinol 2010;26:237-239.
15. Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21-28. (Pubitemid 40692595)
16. Nathorst-Böös J, von Schoultz B, Carlström K. Elective ovarian removal and estrogen replacement therapy-effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 1993;14:283-293. (Pubitemid 24016900)
17. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-409. (Pubitemid 17138572)
18. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005;CD004509.
19. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-5233. (Pubitemid 41262278)
20. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006;13:770-779.
21. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Ribot J, Rees M, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;13:387-396.
22. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, et al.; APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005-2017.
23. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, Rees M, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121-131.
24. Traish AM, Feeley RJ, Guay AT. Testosterone therapy in women with gynecological and sexual disorders: a triumph of clinical endocrinology from 1938 to 2008. J Sex Med 2009;6:334-351.
25. Panzer C, Guay A. Testosterone replacement therapy in naturally and surgically menopausal women. J Sex Med 2009;6:8-18.
26. Krapf JM, Simon JA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas 2009;63:213-219.
27. Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res 2009;11:212.
28. Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63:63-66.
29. Baglietto L, English DR, Hopper JL, MacInnis RJ, Morris HA, Tilley WD, Krishnan K, Giles GG. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 2009;115:171-179.
30. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzisouer KJ, Alberg AJ, Rollison DE, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. B J Cancer 2009;23:709-722.
31. Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri RL, Rosner BA, Colditz GA, Hankinson SE. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer 2010;126:199-207.
32. Ho CC, Rohaizak M, Zulkifli SZ, Siti-Aishah MA, Nor-Aini U, Sharifah- Noor-Akmal SH. Serum sex hormone levels in pre- and postmenopausal breast cancer patients. Singapore Med J 2009;50:513-518.
33. Secreto G, Venturelli E, Meneghini E, Greco M, Ferraris C, Gion M, Zancan M, et al. Testosterone and biological characteristics of breast cancers in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2009;18:2942-2948.
34. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008;630:148-165.
35. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2009;18:169-176.
36. Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C, Henderson BE, et al. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. Endocr Relat Cancer 2010;17:125-134.
37. Davis SR, Hirschberg AL, Wagner LK, Lodhi I, von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J Clin Endocrinol Metab 2009;94:4907-4913.
38. van Staa TP, Sprafka JM. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009;62:76-80.
39. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009;169:41-46.
40. Jick SS, Hagberg KW, Kaye JA, Jick H. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. Obstet Gynecol 2009;113:74-80.
41. Bitzer J, Kenemans P, Mueck AO; FSDeducation Group. Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy. Maturitas 2008;59:209-218.
42. Wood CE, Lees CJ, Cline JM. Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesterone. Menopause 2009;16:466-476.
43. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med 2008;5:765-776. (Pubitemid 351472186)
44. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008;159:197-202.
45. Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 1997;70:150-154. (Pubitemid 27107409)
46. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009;113:1027-1037.
47. Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 2006;13:129-136.
48. Miki Y, Suzuki T, Sasano H. Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. J Steroid Biochem Mol Biol 2009;114:68-71.
49. Shufelt CL, Braunstein GD. Testosterone and the breast. Menopause Int 2008;14:117-122.
50. Orwell G. Animal farm: a fairy story. London: Secker and Warburg; 1945.
51. Kenemans P. Personal communication with Andrea Genazzani; 1995.